EN 
ES 
Novo Nordisk A/S
Monthly Valuation – Valutico | December 23, 2024
Treating chronic diseases
Novo Nordisk, a Danish pharmaceutical leader, is renowned for its expertise in diabetes, obesity care, hemophilia and other chronic diseases. Its drug portfolio includes popular weight loss medications Ozempic and Wegovy, which have transformed obesity treatment globally. The company also produces 50% of the world’s insulin supply and conducts clinical trials in over 40 countries.
Faring well in Q3
The Company reported 24% sales growth and 22% operating profit growth for the first nine months of 2024, driven by strong demand for GLP-1 (glucagon-like peptide-1) treatments, including Ozempic and Wegovy. However, periodic supply constraints and drug shortages impacted availability across regions.
Strategic moves
Novo Holdings, the parent company, recently completed the acquisition of Catalent, Inc., a U.S.-based contract manufacturing organization, for $16.5 billion. This strategic acquisition will add three new manufacturing facilities and enhance production capacity for Wegovy, helping meet growing demand.
Rising competition
The obesity treatment market is becoming more competitive, with licensed generic versions of Novo Nordisk’s weight-loss drugs and products from competitors like Eli Lilly challenging its market share. The World Health Organization (WHO) has also raised awareness of the benefits and risks associated with weight-loss medications, adding to the industry’s scrutiny.
Stock drop
Last week, the Company’s shares plunged over 20%, driven by underwhelming weight loss results from trials of its experimental next-generation obesity drug, CagriSema.
Valutico’s view
Our recent analysis indicates that Novo Nordisk is currently fairly valued. A DCF valuation estimates its equity value at approximately DKK 5,800 billion, while Trading Comparables suggest a lower range of DKK 1,500–1,800 billion. Its significantly higher trading multiples reflect market optimism about products like Ozempic and Wegovy, as well as its superior profit margins compared to peers.
Road ahead
Novo Nordisk is investing in R&D and expanding production to stay competitive in obesity and diabetes care. While strategic acquisitions and innovations strengthen its position, challenges like increased competition, regulatory scrutiny, and market volatility could impact its future trajectory.
Disclaimer
This overview is for informational purposes and not financial advice. Always conduct thorough research and consult financial experts before making any investment decisions.
